{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:55:58Z","timestamp":1791309358513,"version":"4.3.1"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior Reports"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ebr.2022.100581","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T12:56:33Z","timestamp":1672232193000},"page":"100581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters"],"prefix":"10.1016","volume":"21","author":[{"given":"Steve","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurriaan M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Detyniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebr.2022.100581_b0005","unstructured":"Bausch Health Companies Inc. Migranal nasal spray (dihydrorgotamine mesylate). Full Prescribing Information. Bausch Health Companies Inc.; 2022."},{"key":"10.1016\/j.ebr.2022.100581_b0010","unstructured":"GlaxoSmithKline. Imitrex nasal spray (sumatriptan). Full Prescribing Information. GlaxoSmithKline; 2017."},{"key":"10.1016\/j.ebr.2022.100581_b0015","series-title":"Zomig (zolmitriptan spray, metered)","author":"Pharmaceuticals","year":"2019"},{"key":"10.1016\/j.ebr.2022.100581_b0020","series-title":"Nayzilam (midazolam) NDA approval","author":"US Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.ebr.2022.100581_b0025","series-title":"Spravato nasal spray (esketamine)","author":"Pharmaceuticals","year":"2020"},{"key":"10.1016\/j.ebr.2022.100581_b0030","unstructured":"Adapt Pharma, Inc. Narcan\u00ae Nasal Spray (naloxone hydrochloride). Full Prescribing Information. Plymouth Meeting, PA: Adapt Pharma, Inc.; 2020."},{"key":"10.1016\/j.ebr.2022.100581_b0035","series-title":"Nayzilam\u00ae (midazolam nasal spray). Full Prescribing Information","author":"UCB, Inc.,","year":"2021"},{"key":"10.1016\/j.ebr.2022.100581_b0040","unstructured":"Neurelis, Inc. VALTOCO (diazepam nasal spray). Full Prescribing Information. San Diego, CA: Neurelis, Inc.; 2022."},{"key":"10.1016\/j.ebr.2022.100581_b0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0050","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/14737175.2021.1965880","article-title":"A review of a diazepam nasal spray for the treatment of acute seizure clusters and prolonged seizures","volume":"21","author":"Higdon","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ebr.2022.100581_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106748","article-title":"A systematic review of seizure clusters: prevalence, risk factors, burden of disease and treatment patterns","volume":"177","author":"Chung","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2022.100581_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107391","article-title":"Seizure clusters, rescue treatments, seizure action plans: unmet needs and emerging formulations","volume":"112","author":"Gidal","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","article-title":"Seizure cluster: definition, prevalence, consequences, and management","volume":"68","author":"Jafarpour","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2022.100581_b0070","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/epi.16847","article-title":"Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters","volume":"62","author":"Cloyd","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0075","unstructured":"US Food and Drug Administration. FDA Approved Drugs: NDA: 020648 - Diastat (diazepam rectal gel) Drug Approval, http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=020648 1997 [accessed Jan 21, 2022]."},{"key":"10.1016\/j.ebr.2022.100581_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eplepsyres.2010.10.001","article-title":"Diazepam autoinjector intramuscular delivery system versus diazepam rectal gel: a pharmacokinetic comparison","volume":"93","author":"Garnett","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2022.100581_b0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1525-5050(02)00559-0","article-title":"Adult patient perceptions of emergency rectal medications for refractory seizures","volume":"3","author":"Tatum","year":"2002","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0090","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/epi.16279","article-title":"Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants","volume":"60","author":"French","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0095","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.ebr.2022.100581_b0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.ebr.2022.100581_b0105","series-title":"2019","author":"Wheless JW, Sperling, M.R., Liow, K., et al. Safety of Valtoco (NRL-1; diazepam nasal spray) in patients with epilepsy: interim results from a phase 3, open-label, 12-month repeat dose study. Presented at: American Epilepsy Society","year":"2019"},{"key":"10.1016\/j.ebr.2022.100581_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108013","article-title":"Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: results from an exit survey of a phase 3, open-label, repeat-dose safety study","volume":"121","author":"Penovich","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.yebeh.2018.12.007","article-title":"A hospital-based study on caregiver preferences on acute seizure rescue medications in pediatric patients with epilepsy: intranasal midazolam versus rectal diazepam","volume":"92","author":"Nunley","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.ebr.2022.100581_b0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ebr.2022.100581_b0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erdo","year":"2018","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.ebr.2022.100581_b0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.ebr.2022.100581_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"Ganger","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ebr.2022.100581_b0145","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1073\/pnas.1620194114","article-title":"Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells","volume":"114","author":"Pizzolla","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebr.2022.100581_b0150","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ebr.2022.100581_b0155","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.ebr.2022.100581_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118635","article-title":"Strategies to facilitate or block nose-to-brain drug delivery","volume":"570","author":"Martins","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ebr.2022.100581_b0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4187\/respcare.02568","article-title":"Growth of nasal and laryngeal airways in children: implications in breathing and inhaled aerosol dynamics","volume":"59","author":"Xi","year":"2014","journal-title":"Respir Care"},{"key":"10.1016\/j.ebr.2022.100581_b0170","first-page":"413","article-title":"A longitudinal study of nasal airway size from age 9 to age 13","volume":"69","author":"Crouse","year":"1999","journal-title":"Angle Orthod"},{"key":"10.1016\/j.ebr.2022.100581_b0175","doi-asserted-by":"crossref","first-page":"20190261","DOI":"10.1098\/rstb.2019.0261","article-title":"Olfaction scaffolds the developing human from neonate to adolescent and beyond","volume":"375","author":"Schaal","year":"2020","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.ebr.2022.100581_b0180","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1164\/ajrccm.157.6.9709019","article-title":"Innervation of nasal turbinate blood vessels in rhinitic and nonrhinitic children","volume":"157","author":"Figueroa","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebr.2022.100581_b0185","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ijporl.2014.03.012","article-title":"A general review of the otolaryngologic manifestations of Down syndrome","volume":"78","author":"Chin","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.ebr.2022.100581_b0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2500\/ajr.2008.22.3147","article-title":"Reference values for acoustic rhinometry in children from 4 to 13 years old","volume":"22","author":"Straszek","year":"2008","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.ebr.2022.100581_b0195","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.rmed.2013.07.021","article-title":"Nasal flow, volumes, and minimal cross sectional areas in asthmatics","volume":"107","author":"Thorstensen","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.ebr.2022.100581_b0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/jam.2006.19.92","article-title":"Nasal clearance in health and disease","volume":"19","author":"Illum","year":"2006","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.ebr.2022.100581_b0205","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0169-409X(97)00066-5","article-title":"Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption","volume":"29","author":"Donovan","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebr.2022.100581_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107898","volume":"118","author":"Vazquez","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ebr.2022.100581_b0220","series-title":"All Around the Nose","first-page":"65","article-title":"Mucociliary Clearance and Its Importance","author":"Edizer","year":"2020"},{"key":"10.1016\/j.ebr.2022.100581_b0225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/thorax.58.4.333","article-title":"Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults","volume":"58","author":"Chilvers","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.ebr.2022.100581_b0230","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/000348949110000506","article-title":"Human in vitro nasal and tracheal ciliary beat frequencies: comparison of sampling sites, combined effect of medication, and demographic relationships","volume":"100","author":"Roth","year":"1991","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.ebr.2022.100581_b0235","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebr.2022.100581_b0240","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jps.2600760709","article-title":"Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity","volume":"76","author":"McMartin","year":"1987","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ebr.2022.100581_b0245","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.ebr.2022.100581_b0250","first-page":"641","article-title":"Countercurrent transfer of dopamine from venous blood in the cavernous sinus to the arterial blood supplying the brain - the perfused rabbit head as an experimental model","volume":"65","author":"Muszak","year":"2014","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.ebr.2022.100581_b0255","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1034\/j.1600-0773.2000.pto870606.x","article-title":"Local transfer of diazepam, but not of cocaine, from the nasal cavities to the brain arterial blood in rats","volume":"87","author":"Einer-Jensen","year":"2000","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.ebr.2022.100581_b0260","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1743-8454-1-2","article-title":"Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species","volume":"1","author":"Johnston","year":"2004","journal-title":"Cerebrospinal Fluid Res"},{"key":"10.1016\/j.ebr.2022.100581_b0265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpharm.2008.07.030","article-title":"Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits","volume":"364","author":"Kaur","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ebr.2022.100581_b0270","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00688493","article-title":"Uptake of exogenous proteins in mouse olfactory cells","volume":"19","author":"Kristensson","year":"1971","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ebr.2022.100581_b0275","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.114.216705","article-title":"Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin","volume":"351","author":"Falcone","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ebr.2022.100581_b0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.58.1.0008","article-title":"Carbamazepine uptake into rat brain following intra-olfactory transport","volume":"58","author":"Barakat","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ebr.2022.100581_b0285","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717549709051878","article-title":"Delivery of125I-NGF to the brain via the olfactory route","volume":"4","author":"Frey","year":"2008","journal-title":"Drug Deliv"},{"key":"10.1016\/j.ebr.2022.100581_b0290","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejps.2005.01.009","article-title":"Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents","volume":"24","author":"Westin","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ebr.2022.100581_b0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/(SICI)1099-081X(199812)19:9<571::AID-BDD142>3.0.CO;2-O","article-title":"Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat","volume":"19","author":"Wang","year":"1998","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.ebr.2022.100581_b0300","doi-asserted-by":"crossref","unstructured":"T.M. Ross P.M. Martinez J.C. Renner R.G. Thorne L.R. Hanson W.H. Frey Intranasal administration of interferon beta bypasses the blood\u2013brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis J Neuroimmunol 2004;151:66-77. doi: 10.1016\/j.jneuroim.2004.02.011.","DOI":"10.1016\/j.jneuroim.2004.02.011"},{"key":"10.1016\/j.ebr.2022.100581_b0305","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.ebr.2022.100581_b0310","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ebr.2022.100581_b0315","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/jam.2007.0638","article-title":"The influence of spray properties on intranasal deposition","volume":"20","author":"Foo","year":"2007","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.ebr.2022.100581_b0320","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/pharmaceutics6020195","article-title":"Analytical challenges and regulatory requirements for nasal drug products in Europe and the U.S","volume":"6","author":"Trows","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ebr.2022.100581_b0325","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5414\/CP201825","article-title":"Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl","volume":"51","author":"Perelman","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ebr.2022.100581_b0330","first-page":"83","article-title":"Vasomotor rhinitis and the systemic absorption of ipratropium bromide","volume":"28","author":"Kaila","year":"1990","journal-title":"Rhinology"},{"key":"10.1016\/j.ebr.2022.100581_b0335","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/j.1552-4604.1994.tb02051.x","article-title":"Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide","volume":"34","author":"Argenti","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ebr.2022.100581_b0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00202176","article-title":"Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant","volume":"48","author":"Lunell","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ebr.2022.100581_b0345","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13346-012-0069-z","article-title":"High efficiency intranasal drug delivery using Intravail\u00ae alkylsaccharide absorption enhancers","volume":"3","author":"Maggio","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.ebr.2022.100581_b0350","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5173(99)00451-2","article-title":"Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts","volume":"197","author":"Tengamnuay","year":"2000","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ebr.2022.100581_b0355","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1248\/bpb.18.734","article-title":"Effects of dose, pH and osmolarity on intranasal absorption of recombinant human erythropoietin in rats","volume":"18","author":"Shimoda","year":"1995","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ebr.2022.100581_b0360","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1023\/A:1007551927177","article-title":"Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects","volume":"17","author":"Ahmed","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.ebr.2022.100581_b0365","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jps.2600760905","article-title":"Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. II: histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity","volume":"76","author":"Ohwaki","year":"1987","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ebr.2022.100581_b0370","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40268-021-00360-5","article-title":"Improvement of intranasal drug delivery with Intravail\u00ae alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system","volume":"21","author":"Rabinowicz","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.ebr.2022.100581_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106567","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray","volume":"171","author":"Bouw","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2022.100581_b0380","series-title":"Drug Discovery and Development \u2014 From Molecules to Medicine","first-page":"299","article-title":"Intranasal drug administration \u2014 an attractive delivery route for some drugs","author":"Marx","year":"2015"},{"key":"10.1016\/j.ebr.2022.100581_b0385","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1111\/epi.13131","article-title":"Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers","volume":"56","author":"Bancke","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0390","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/epi.16300","article-title":"Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial","volume":"60","author":"Wheless","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0395","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0169-409X(97)00067-7","article-title":"Nasal delivery systems and their effect on deposition and absorption","volume":"29","author":"Vidgren","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebr.2022.100581_b0400","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40122-019-0118-0","article-title":"Comparative human factors evaluation of two nasal naloxone administration devices: NARCAN\u00ae nasal spray and naloxone prefilled syringe with nasal atomizer","volume":"8","author":"Tippey","year":"2019","journal-title":"Pain Ther"},{"key":"10.1016\/j.ebr.2022.100581_b0405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2431-14-67","article-title":"Utility of intranasal ketamine and midazolam to perform gastric aspirates in children: a double-blind, placebo controlled, randomized study","volume":"14","author":"Buonsenso","year":"2014","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.ebr.2022.100581_b0410","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1017\/S1049023X13003579","article-title":"Effect of introducing the mucosal atomization device for fentanyl use in out-of-hospital pediatric trauma patients","volume":"28","author":"O'Donnell","year":"2013","journal-title":"Prehosp Disaster Med"},{"key":"10.1016\/j.ebr.2022.100581_b0415","unstructured":"Neurelis, Inc. VALTOCO. Instructions for use for 5 mg and 10 mg doses 2022."},{"key":"10.1016\/j.ebr.2022.100581_b0420","article-title":"Aptar Brochure: Nasal spray device with uni-dose and bi-dose systems","author":"Pharma","year":"2016","journal-title":"In"},{"key":"10.1016\/j.ebr.2022.100581_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108264","article-title":"Recommendations for development of acute seizure action plans (ASAPs) from an expert panel","volume":"123","author":"Penovich","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0430","first-page":"12","article-title":"A Short review on the intranasal delivery of diazepam for treating acute repetitive seizures","author":"Boddu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ebr.2022.100581_b0435","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/epi.14069","article-title":"Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats","volume":"59","author":"Dhir","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0440","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.1875-9114.1985.tb03411.x","article-title":"Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia","volume":"5","author":"Kanto","year":"1985","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ebr.2022.100581_b0445","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/jnnp.44.10.914","article-title":"Rectal diazepam in the treatment of absence status: a pharmacodynamic study","volume":"44","author":"Milligan","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ebr.2022.100581_b0450","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/acn3.50932","article-title":"Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study","volume":"6","author":"Kay","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ebr.2022.100581_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108550","article-title":"Comment on \u201cIntranasal midazolam versus intravenous\/rectal benzodiazepines for acute seizure control in children: a systematic review and meta-analysis\u201d","volume":"128","author":"Wheless","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0460","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/epi.17041","article-title":"Final results from a phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy","volume":"62","author":"Wheless","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0465","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/epi.15159","article-title":"Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Detyniecki","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108390","article-title":"Intranasal midazolam versus intravenous\/rectal benzodiazepines for acute seizure control in children: a systematic review and meta-analysis","volume":"125","author":"Chhabra","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100581_b0475","first-page":"1610","article-title":"An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance","volume":"40","author":"Mitchell","year":"1999","journal-title":"North American Diastat Group Epilepsia"},{"key":"10.1016\/j.ebr.2022.100581_b0480","unstructured":"Bausch Health US, LLC. Diastat\u00ae C-IV (diazepam rectal gel). Full Prescribing Information. Bridgewater, NJ: Bausch Health US, LLC; 2021."},{"key":"10.1016\/j.ebr.2022.100581_b0485","unstructured":"J.W. Wheless M. Brunnert F. Floricel S. Dimova B. Fannon Early intervention with midazolam nasal spray and efficacy in patients with seizure clusters: post-hoc analysis of an open-label extension trial Presented at: American Epilepsy Society Annual Meeting December 3\u20137, 2021, 2021; Chicago."},{"key":"10.1016\/j.ebr.2022.100581_b0490","first-page":"1","article-title":"Local and systemic safety of intranasal corticosteroids","volume":"22","author":"Sastre","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.ebr.2022.100581_b0495","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7150\/thno.22711","article-title":"Recent advances in the application of vitamin E TPGS for drug delivery","volume":"8","author":"Yang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ebr.2022.100581_b0500","first-page":"11","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ebr.2022.100581_b0505","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.eplepsyres.2013.02.018","article-title":"A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers","volume":"105","author":"Agarwal","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2022.100581_b0510","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1528-1157.1998.tb01415.x","article-title":"A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam","volume":"39","author":"Cloyd","year":"1998","journal-title":"Epilepsia"}],"container-title":["Epilepsy &amp; Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986422000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986422000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:08:41Z","timestamp":1762906121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986422000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":102,"alternative-id":["S2589986422000582"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2022.100581","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2022.100581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100581"}}